bromocriptine has been researched along with quinagolide in 62 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.61) | 18.7374 |
1990's | 38 (61.29) | 18.2507 |
2000's | 12 (19.35) | 29.6817 |
2010's | 8 (12.90) | 24.3611 |
2020's | 3 (4.84) | 2.80 |
Authors | Studies |
---|---|
Brue, T; Jaquet, P; Morange, I; Pellegrini, I; Priou, A | 1 |
Caruso, E; Colao, A; Di Sarno, A; Di Somma, C; Lombardi, G; Merola, B; Sarnacchiaro, F | 1 |
Brownell, J; Brue, T; Dewailly, D; Enjalbert, A; Gunz, G; Jaquet, P; Morange, I; Pellegrini, I | 1 |
Blackwell, RE | 1 |
Brownell, J; Lappöhn, RE; van de Wiel, HB | 1 |
Chanson, P; Duranteau, L; Horlait, S; Kuhn, JM; Lavoinne, A; Lubetzki, J | 1 |
Brownell, J; Kremer, JA; Rolland, R; van der Heijden, PF | 1 |
Brownell, J; Lamberts, SW; van der Lely, AJ | 1 |
Brownell, J; de Wit, W; Rolland, R; Schoemaker, J; van der Heijden, PF | 1 |
Geyer, G; Knosp, E; Luger, A; Svoboda, T | 1 |
Besser, GM; Froud, AL; Grossman, AB; Touzel, R; Verhelst, JA; Wass, JA | 1 |
Brownell, J; Crottaz, B; Gomez, F; Rey, F; Reymond, MJ; Siegel, RA; Uske, A | 1 |
Philosophe, R; Seibel, MM | 1 |
Brownell, J; Homburg, R; Jacobs, HS; West, C | 1 |
Brownell, J; Kremer, JA; Rolland, R; Schellekens, LA; Thomas, CM; van der Heijden, PF | 1 |
Rasmussen, C | 1 |
Hurley, AM; Kleinberg, DL; Newman, CB | 1 |
Becker, W; Buchfelder, M; Fahlbusch, R; Horvath, E; Kovacs, K; Stefaneanu, L | 1 |
Colao, A; Di Sarno, A; Di Somma, C; Ferone, D; Landi, ML; Merola, B; Nappi, C; Sarnacchiaro, F; Schettini, G; Selleri, A | 1 |
Burke, CW; Vilar, L | 1 |
Chevallier, P; Claustrat, B; Dubray, C; Girod, C; Hooghe-Peters, E; Rousset, B; Trouillas, J | 1 |
Beardwell, CG; O'Halloran, DJ; Razzaq, R; Shalet, SM | 1 |
Barziliai, S; Glaser, B; Nesher, Y | 1 |
Blackard, WG | 1 |
Bakke, S; Bjøro, T; Brownell, J; Djøseland, O; Halse, J; Hansen, E; Jervell, J; Kvistborg, A | 1 |
Attanasio, R; Chiodini, PG; Cozzi, R; Dallabonzana, D; Liuzzi, A; Oppizzi, G; Orlandi, P; Strada, S | 1 |
Assies, J; Bosch, DA; Hofland, LJ; Verhoeff, NP | 1 |
Cerbone, G; Colao, A; Di Sarno, A; Ferone, D; Landi, ML; Lombardi, G; Marzullo, P; Merola, B; Sarnacchiaro, F | 1 |
Webster, J | 1 |
Barlier, A; Brue, T; Enjalbert, A; Jaquet, P; Morange, I; Pellegrini, I | 1 |
Cerbone, G; Cirillo, S; Colao, A; Di Sarno, A; Ferone, D; Lombardi, G; Marzullo, P; Merola, B; Sarnacchiaro, F | 1 |
Jaquet, P | 2 |
De Herder, WW; Hofland, LJ; Kros, MJ; Lamberts, SW; Uitterlinden, P; Van Koetsveld, PM; Van Uffelen, C; Visser-Wisselaar, HA; Waaijers, M; Zuyderwijk, J | 1 |
Colao, A; Di Sarno, A; Di Somma, C; Facciolli, G; Klain, M; Landi, ML; Lombardi, G; Panza, N; Pivonello, R; Salvatore, M | 1 |
Conner, P; Fried, G | 1 |
Crabbé, J; Delgrange, E; Donckier, J | 1 |
Cappa, M; Colao, A; Di Sarno, A; Facciolli, G; Landi, ML; Loche, S; Lombardi, G; Sarnacchiaro, F | 1 |
Colao, A; Di Sarno, A; Di Somma, C; Klain, M; Loche, S; Lombardi, G; Pietrosante, M; Pivonello, R; Salvatore, M | 1 |
Hulting, AL; Melkersson, K | 1 |
Freneau, E; Morange, I; Rohmer, V; Simonetta, C | 1 |
Colao, A; di Sarno, A; di Somma, C; Lombardi, G; Pivonello, R | 1 |
Bankowski, BJ; Zacur, HA | 1 |
Trifonov, I | 1 |
Goadsby, PJ; Levy, MJ; Matharu, MS; Meeran, K; Powell, M | 1 |
Crosignani, PG | 1 |
Bronstein, MD | 1 |
Barlier, A; Jaquet, P | 1 |
Chuang, E; Molitch, ME | 1 |
Mezosi, E; Nemes, O | 1 |
Adamidou, F; Anagnostis, P; Efstathiadou, Z; Karathanassi, E; Kita, M; Polyzos, SA | 1 |
Boutinaud, M; Bruckmaier, RM; Dessauge, F; Lacasse, P; Lollivier, V; Ollier, S | 1 |
Góth, M | 1 |
Beketić-Orešković, L; Ježek, D; Kasum, M; Orešković, S; Pekez, M; Stanić, P; Vrčić, H | 1 |
Chapman, IM; De Sousa, SM; Falhammar, H; Torpy, DJ | 1 |
Hart, RJ; Mourad, S; Tang, H; Zhai, SD | 1 |
Beckers, A; Bonneville, JF; Brue, T; Castinetti, F; Cuny, T; Dufour, H; Eroukhmanoff, J; Potorac, I; Tejedor, I; Touraine, P; Weryha, G | 1 |
Čehić, E; Franulić, D; Grgić, F; Kasum, M; Lila, A; Orešković, S; Vujić, G | 1 |
Hart, RJ; Mourad, SM; Tang, H; Wang, A; Zhai, SD | 1 |
Auriemma, RS; Colao, A; Negri, M; Patalano, R; Pirchio, R; Pivonello, C; Pivonello, R | 1 |
Huang, Q; Li, M; Tan, J; Zeng, Y; Zhou, W; Zou, Y | 1 |
21 review(s) available for bromocriptine and quinagolide
Article | Year |
---|---|
Hyperprolactinemia. Evaluation and management.
Topics: Aminoquinolines; Animals; Bromocriptine; Dopamine Agents; Female; Humans; Hyperprolactinemia; Infertility; Ovary; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma | 1992 |
Novel approaches to the management of hyperprolactinemia.
Topics: Aminoquinolines; Bromocriptine; Dopamine Agents; Female; Humans; Hyperprolactinemia; Pergolide | 1991 |
New drugs for hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Clinical Trials as Topic; Ergolines; Hormone Antagonists; Humans; Hyperprolactinemia | 1995 |
A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Lactation; Male; Pregnancy | 1996 |
[Quinagolide and macroprolactinomas a progress?].
Topics: Aminoquinolines; Bromocriptine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 1997 |
Hyperprolactinemia; etiology, diagnosis and treatment alternatives.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Pergolide; Prolactin; Receptors, Prolactin | 1998 |
Dopamine receptor agonists for treating prolactinomas.
Topics: Aminoquinolines; Animals; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Ergot Alkaloids; Female; Humans; Pergolide; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma | 2002 |
Dopamine agonist therapy for hyperprolactinemia.
Topics: Aminoquinolines; Benzothiazoles; Bromocriptine; Cabergoline; Clinical Trials as Topic; Dopamine Agonists; Ergolines; Ergoloid Mesylates; Female; Humans; Hyperprolactinemia; Indoles; Pergolide; Pramipexole; Thiazoles | 2003 |
[Prolactinoma and pregnancy].
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2004 |
Current treatment issues in female hyperprolactinaemia.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Pituitary Neoplasms; Pregnancy; Prolactinoma | 2006 |
Prolactinomas and pregnancy.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Child; Dopamine Agonists; Ergolines; Female; Humans; Magnetic Resonance Imaging; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma | 2005 |
Quinagolide--a valuable treatment option for hyperprolactinaemia.
Topics: Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Hyperprolactinemia; Male; Patient Compliance | 2006 |
[Treatment of pituitary adenomas].
Topics: Acromegaly; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Aminoquinolines; Bromocriptine; Cushing Syndrome; Dopamine Agonists; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypophysectomy; Incidental Findings; Male; Pituitary Hormones; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prolactinoma; Radiosurgery; Receptors, Somatotropin; Somatostatin; Thyrotropin | 2009 |
New developments on the galactopoietic role of prolactin in dairy ruminants.
Topics: Aminoquinolines; Animals; Bromocriptine; Cattle; Dopamine Agonists; Female; Lactation; Lactose; Milk; Milk Proteins; Prolactin | 2012 |
[Drug therapy for acromegaly].
Topics: Acromegaly; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Interdisciplinary Communication; Membrane Proteins; Octreotide; Patient Care Team; Peptides, Cyclic; Pituitary Neoplasms; Somatostatin | 2013 |
Dopamine agonists in prevention of ovarian hyperstimulation syndrome.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction | 2014 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Reproductive Techniques, Assisted | 2016 |
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome
Topics: Aminoquinolines; Bromocriptine; Buserelin; Cabergoline; Chorionic Gonadotropin; Dopamine Agonists; Ergolines; Estradiol; Estrogens; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Oocyte Retrieval; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone; Progestins; Triptorelin Pamoate | 2017 |
Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Fertilization in Vitro; Humans; Live Birth; Ovarian Hyperstimulation Syndrome; Placebos; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic | 2021 |
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aminoquinolines; beta-Arrestins; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Filamins; Growth Hormone-Secreting Pituitary Adenoma; Humans; Lisuride; MicroRNAs; Pergolide; Pituitary Neoplasms; Prolactinoma; Receptors, Dopamine D2 | 2021 |
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperprolactinemia; Pituitary Neoplasms | 2023 |
15 trial(s) available for bromocriptine and quinagolide
Article | Year |
---|---|
The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia.
Topics: Adult; Amenorrhea; Aminoquinolines; Bromocriptine; Depression; Dopamine Agents; Female; Humans; Hyperprolactinemia; Menstruation; Oligomenorrhea; Prolactin; Prospective Studies; Psychological Tests | 1992 |
Lactation inhibition by the dopamine agonist CV 205-502.
Topics: Administration, Oral; Aminoquinolines; Blood Coagulation Tests; Bromocriptine; Dopamine Agents; Drug Administration Schedule; Electrocardiography; Female; Humans; Lactation; Pilot Projects; Postpartum Period; Pregnancy; Prolactin; Pulse | 1991 |
The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
Topics: Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors | 1991 |
CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.
Topics: Adolescent; Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Double-Blind Method; Drug Evaluation; Drug Tolerance; Female; Galactorrhea; Humans; Hyperprolactinemia; Menstrual Cycle; Middle Aged; Patient Compliance; Prolactin | 1991 |
[Treatment of prolactinoma with a new dopamine agonist].
Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Dopamine Agents; Female; Humans; Lisuride; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors | 1991 |
Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Topics: Adult; Aminoquinolines; Blood Pressure; Bromocriptine; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Female; Hormones; Humans; Hyperprolactinemia; Male; Middle Aged; Prolactin; Time Factors | 1991 |
A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
Topics: Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Double-Blind Method; Female; Humans; Hyperprolactinemia; Iodine Radioisotopes; Menstruation; Middle Aged; Prolactin; Radioimmunoassay; Randomized Controlled Trials as Topic | 1990 |
Hyperprolactinaemia--a clinical study with special reference to long-term follow-up, treatment with dopamine agonists, and pregnancy.
Topics: Adolescent; Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Menstruation; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Prolactin; Radiography; Sella Turcica | 1990 |
Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
Topics: Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Drug Evaluation; Drug Tolerance; Female; Humans; Hyperprolactinemia; Menstruation Disturbances; Middle Aged; Prolactin | 1989 |
Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Topics: Administration, Oral; Adult; Aminoquinolines; Bromocriptine; Delayed-Action Preparations; Dopamine Agonists; Drug Resistance; Female; Humans; Hyperprolactinemia; Magnetic Resonance Imaging; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Time Factors; Tomography, X-Ray Computed | 1994 |
Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.
Topics: Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Drug Tolerance; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies | 1994 |
Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Topics: Administration, Oral; Adolescent; Adult; Aminoquinolines; Bromocriptine; Dopamine Agonists; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Treatment Outcome | 1994 |
Long-term treatment of macroprolactinomas with CV 205-502.
Topics: Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Drug Tolerance; Erectile Dysfunction; Estradiol; Female; Humans; Libido; Longitudinal Studies; Male; Menstruation; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Radioimmunoassay; Sex Hormone-Binding Globulin; Testosterone; Visual Fields | 1993 |
Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Topics: Administration, Oral; Adolescent; Adult; Aminoquinolines; Bromocriptine; Dopamine Agonists; Female; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Radioimmunoassay; Reagent Kits, Diagnostic; Tomography, X-Ray Computed | 1995 |
Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Topics: Adult; Aminoquinolines; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hyperprolactinemia; Male; Middle Aged; Prospective Studies | 1998 |
26 other study(ies) available for bromocriptine and quinagolide
Article | Year |
---|---|
Prolactinomas and resistance to dopamine agonists.
Topics: Adolescent; Adult; Aminoquinolines; Bromocriptine; Child; Drug Resistance; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 1992 |
Usefulness of CV 205-502 in a case of allergy to ergot-derived drugs.
Topics: Adult; Aminoquinolines; Bromocriptine; Drug Hypersensitivity; Female; Humans; Lisuride; Pituitary Neoplasms; Prolactin; Prolactinoma | 1992 |
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Topics: Adult; Aminoquinolines; Antineoplastic Agents; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Resistance; Female; Growth Hormone; Humans; Luteinizing Hormone; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Tomography, X-Ray Computed; Triiodothyronine; Tumor Cells, Cultured | 1992 |
Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Dopamine Agents; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Prospective Studies; Retrospective Studies | 1991 |
CV 205-502 treatment of macroprolactinomas.
Topics: Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Drug Resistance; Endocrine System Diseases; Female; Galactorrhea; Gonads; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 1991 |
Postpartum return of pituitary and ovarian activity during lactation inhibition with the new dopamine agonist CV 205-502 and during normal lactation.
Topics: Aminoquinolines; Bromocriptine; Dopamine Agents; Estradiol; Female; Fertility; Follicle Stimulating Hormone; Humans; Lactation; Luteinizing Hormone; Ovary; Pituitary Gland; Postpartum Period; Prolactin | 1990 |
Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report.
Topics: Adenoma; Adolescent; Aminoquinolines; Bromocriptine; Dopamine Agonists; Drug Resistance; Female; Humans; Microscopy, Electron; Pituitary Neoplasms; Prolactin; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Estrogen; RNA, Messenger | 1995 |
Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat.
Topics: Aminoquinolines; Animals; Bromocriptine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Neoplasm Transplantation; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred WF; Ultrasonography | 1994 |
The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.
Topics: Adult; Amenorrhea; Aminoquinolines; Bromocriptine; Dopamine Agents; Drug Resistance; Drug Tolerance; Female; Galactorrhea; Humans; Hyperprolactinemia; Middle Aged; Pregnancy; Prolactin | 1993 |
Edema--an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs.
Topics: Aminoquinolines; Bromocriptine; Dopamine Agents; Edema; Humans; Male; Middle Aged; Pergolide; Pituitary Neoplasms; Prolactinoma | 1993 |
CV 205-502 in acromegaly.
Topics: Acromegaly; Adult; Aminoquinolines; Bromocriptine; Dopamine Agents; Female; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Gland; Prolactin; Time Factors | 1993 |
Intracranial dissemination of a macroprolactinoma.
Topics: Aminoquinolines; Brain Neoplasms; Bromocriptine; Combined Modality Therapy; Drug Therapy, Combination; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Radiotherapy Dosage; Somatostatin | 1993 |
Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Topics: Aminoquinolines; Bromocriptine; Dopamine Agonists; Drug Resistance; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prolactinoma | 1996 |
Effect of different dopaminergic agents in the treatment of acromegaly.
Topics: Acromegaly; Adult; Aminoquinolines; Bromocriptine; Cabergoline; Delayed-Action Preparations; Dopamine Agonists; Ergolines; Female; Human Growth Hormone; Humans; Male; Middle Aged; Prolactin | 1997 |
Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Topics: Adenoma; Adenoma, Islet Cell; Aminoquinolines; Bromocriptine; Dopamine Agonists; Endocrine Gland Neoplasms; Hormone Antagonists; Hormones; Humans; Insulinoma; Pancreatic Neoplasms; Pituitary Neoplasms; Prolactinoma; Receptors, Somatostatin; Somatostatin; Tumor Cells, Cultured | 1997 |
Evidence for dopamine agonists in the treatment of acromegaly.
Topics: Acromegaly; Adenoma; Aminoquinolines; Bromocriptine; Dopamine Agonists; Drug Therapy, Combination; Humans; Octreotide; Pituitary Neoplasms; Somatostatin | 1997 |
Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Topics: Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Humans; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma | 1998 |
Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
Topics: Adolescent; Amenorrhea; Aminoquinolines; Bromocriptine; Child; Dopamine Agonists; Drug Resistance; Female; Follow-Up Studies; Galactorrhea; Growth Disorders; Humans; Male; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactinoma; Puberty | 1998 |
Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
Topics: Adolescent; Adult; Aminoquinolines; Analysis of Variance; Biomarkers; Bone Density; Bone Remodeling; Bromocriptine; Cabergoline; Case-Control Studies; Collagen; Collagen Type I; Dopamine Agonists; Ergolines; Female; Femur Neck; Humans; Longitudinal Studies; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis; Peptides; Pituitary Neoplasms; Prolactinoma; Regression Analysis | 2000 |
Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.
Topics: Adult; Aminoquinolines; Antipsychotic Agents; Bipolar Disorder; Bromocriptine; Clozapine; Comorbidity; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Psychoses, Substance-Induced; Psychotic Disorders | 2000 |
Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Topics: Aminoquinolines; Bromocriptine; Dopamine Agonists; Drug Resistance, Neoplasm; Female; Humans; Male; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies | 2000 |
The clinical characteristics of headache in patients with pituitary tumours.
Topics: Adenoma; Adult; Aminoquinolines; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Disability Evaluation; Dopamine Agonists; Ergolines; Female; Headache; Humans; Male; Migraine Disorders; Octreotide; Peptides, Cyclic; Pituitary Neoplasms; Severity of Illness Index; Somatostatin; Time Factors | 2005 |
Prolactin and autoimmune diseases in humans.
Topics: Aminoquinolines; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Bromocriptine; Cabergoline; Cyclosporine; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Hyperprolactinemia; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Mice; Mice, Knockout; Penicillamine; Prednisone; Prolactin; Rats; Receptors, Prolactin | 2007 |
Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prolactinoma; Treatment Outcome; Young Adult | 2012 |
Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
Topics: Adult; Aged; Aminoquinolines; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Humans; Hypogonadism; Male; Middle Aged; Pituitary Neoplasms; Prolactinoma; Retrospective Studies; Sexual Dysfunction, Physiological | 2017 |
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Topics: Adult; Aminoquinolines; Belgium; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Follow-Up Studies; France; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies | 2017 |